Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

Abroad (travel likely)RecruitingPHASE3

Conditions

OligoProgressive Metastatic Disease · Hepatocellular Carcinoma (HCC) · Radiotherapy · Systemic Therapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Jinan, Shandong 0531, Jinan, Shandong, China
Contact: Study coordinator (Jinbo Yue, Doctor) · jbyue@sdfmu.edu.cn · 0531-67626442

Study leads

Jinbo Yue, Doctor
Principal Investigator
Shandong Cancer Hospital and Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)

Prostate Cancer (Adenocarcinoma) · OligoProgressive Metastatic Disease · Castration Resistant Metastatic Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Groningen, Netherlands · Nijmegen, Netherlands

Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer

Metastatic Non-Small Cell Lung Cancer · NSCLC Stage IV · OligoProgressive Metastatic Disease

Abroad (travel likely)RecruitingPHASE3

Hangzhou, China

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

Castrate Resistance Prostate Cancer · OligoProgressive Metastatic Disease

Abroad (travel likely)RecruitingPHASE2

Toronto, Canada

A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

Metastatic Renal Cell Carcinoma · Radiotherapy

Abroad (travel likely)RecruitingPHASE2

Albi, France · Angers, France